Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients

Antiviral Therapy

Volumn 12, Issue 7, 2007, Pages 1127-1132

  Van Der Lee, Manon ^a   Sankatsing, Raaj ^b   Schippers, Emile ^c   Vogel, Martin ^d   Fätkenheuer, Gerd ^e   Van Der Ven, Andre ^a   Kroon, Frank ^c   Rockstroh, Jürgen ^d   Wyen, Christoph ^e   Bäumer, Anselm ^e   De Groot, Eric ^b   Koopmans, Peter ^a   Stroes, Erik ^b   Reiss, Peter ^b   Burger, David ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF BONN   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR PLUS RITONAVIR; ROSUVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMMON COLD SYMPTOM; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; MALE; MUSCLE CRAMP; MYALGIA; PRIORITY JOURNAL; SIDE EFFECT; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FLUOROBENZENES; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MIDDLE AGED; PILOT PROJECTS; PYRIMIDINES; PYRIMIDINONES; RITONAVIR; SULFONAMIDES;

EID: 36148941342     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Calza L, Manfredi R, Chiodo F. Hyperlipidaemia in patients with HIV-I infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents 2003; 22:89-99.
2. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002; 40:2117-2121.
3. Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 2003; 17:851-859.
4. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002; 31:257-275.
5. Carswell CI, Plosker GL, Jarvis B. Rosuvastatin. Drugs 2002; 62:2075-2085.
6. Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 2003; 25:2822-2835.
7. McCormick AD, McKillop D, Butters CJ, et al. ZD-4522: an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human in vitro systems. J Clin Pharmacol 2000; 40:1045-1067.
8. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92:152-160.
9. Crestor. Summary of product characteristics. In: SmPC Crestor .The Medicines Evaluation Board the Netherlands. 2006. CBG-MEB.
10. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37:613-627.
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
12. Droste JAH, Verweij-van Wissen CP, Burger DM Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8 and nevirapine in human plasma by reversed phase high performance liquid chromatography. Ther Drug Monit 2003; 25:393-399.
13. Hull CK, Penman AD, Smith CK, Martin PD. Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 772:219-228.
14. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol 2002; 54:472-477.
15. Martin PD, Dane AL, Schneck DW, Warwick MJ. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 2003; 25:459-471.
16. Simonson SG, Martin PD, Mitchell PD, Lasseter K, Gibson G, Schneck DW. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J Clin Pharmacol 2005; 45:927-934.
17. Calza L, Colangeli V, Manfredi R, et al. Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS 2005; 19:1103-1105.
18. Cheng JW. Rosuvastatin in the management of hyperlipidemia. Clin Ther 2004; 26:1368-1387.
19. Corbett AH, Lim ML, Kashuba AD. Kaletra (lopinavir/ ritonavir). Ann Pharmacother 2002; 36:1193-1203.
20. Kaletra. Summary of Product Characteristics. 16 April 2007. EMEA.
21. Cvetkovic R, Goa K. Lopinavir/Ritonavir : A Review of its Use in the Management of HIV Infection. Drugs 2003; 63:769-802.
22. Norvir. Summary of Product Characteristics. 16 March 2007. EMEA.
23. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzvme A reductase inhibitor. Am J Cardiol. 2001; 87:28B-32B.
24. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002; 58:527-531.
25. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol 2003; 55:94-99.
26. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2003; 59:51-56.
27. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2003; 73:322-329.
28. Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004; 76:167-177.
29. Konig J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000; 278:G156-G164.
30. Brown CDA, Windass A, Bleasby K, Lauffart B. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C. Atherosclerosis Supplements 2002; 2:90.
31. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80:565-581.
32. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006; 34:1229-1236.
33. Hoody D, Kiser J, Predhomme J, Flynn D, Gerber J. Drug-drug interaction between lopinavir/ritonavir and rosuvastatin. 14th Conference on Retroviruses and Opportunistic Infections, 25-28 February 2007, Los Angeles, CA, USA. Abstract 564.
34. Carr RA, Andre AK, Betz RJ, et al. Concommitant administration of ABT-378/ritonavir (ABT-378/r) results in a clinically important pharmacokintics (PK) interaction with atorvastatin (ATO) hut not pravastatin (PRA). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. 17-20 September 2000, Toronto, Canada. Abstract 1644.
35. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16:569-577.
36. Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001; 45:3445-3450.